Atreca, Inc (NASDAQ: BCEL) witnessed a slight gain in its stock price moving into mid-market Thursday trading. BCEL stock saw a small spike in the morning before abruptly retracing, currently holding onto daily gains of 0.5%.
A key driver of the short movement was today’s announcement that Atreca will be entering a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development of a ground-breaking malaria antibody.
BCEL stock has been stuck in a downwards trend for some time, yet a partnership with the Gates MRI is undoubtedly promising. The agreement has been made following findings regarding the disruptive new MAM01/ATRC-501 monoclonal antibody – a powerful new treatment for the prevention of malaria.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The Gates MRI will take over the development of the antibody and will retain commercial rights in GAVI-eligible countries in malaria-endemic regions. Atreca will hold onto commercial rights in the U.S, Europe, and parts of Asia.
Atreca has also received the green light from Roth Capital analyst Tony Butler, who argued a bullish outlook regardless of commercial limitation in the US and Europe – stating the main market opportunity would be for travel to malaria-endemic regions; a first for mainstream modern travel. Although this is a ground-breaking partnership for the treatment of malaria, the likelihood is that it could take a long time to have any effect on the tourism market. Butler issued a price target of $30 for BCEL stock in the coming years – with a current price of $5.28, will Atreca deliver?
